According to Nature.com, Mikhail Blagosklonny is a well-known scientist. He has done many studies on cancer and aging. Moreover, Dr. Blagosklonny has developed unique concepts for cancer, biology, and therapy. Dr. Blagosklonny was a scholar at the First Pavlov State Medical University of St. Peterburg. He attained his M.D in Internal Medicine at the institution.
Mikhail Blagosklonny also attained his Ph.D. in Cardiology and Experimental Medicine at the institution. In 2002, the New York Medical College, Valhalla appointed Dr. Blagosklonny as an Associate Professor of Medicine. After a while, he progressed in his career as a Senior Scientist at the Ordway Research Institute in Albany, New York. He is also the author of hyperfunction theory of aging and anti-cancer approaches known as chemotherapeutic engineering and cell cyclo-therapy.
His field of interest is anti-aging medicine and oncology. Mikhail Blagosklonny focuses on cancer and cancer therapies in-charge of protecting healthy cells from damage. He studies molecular and cellular biology and clinical investigation such as oncogenes, cell cycle, and signal transduction. Dr. Blagosklonny also researches on anti-aging drugs and biogerontology.
Impact Journals also said that Mikhail Blagosklonny formulated a theory about TOR’s potential role in cancer and aging. He formulated this theory using Rapamycin, a drug used for cancer treatment to extend life. The scientist is known to advocate for the use of Rapamycin in longevity research.
In addition to his research, Mikhail Blagosklonny has published several research articles, book chapters, and reviews. He is the editor in chief of the Cell Cycle and co-founder and co-editor of oncotarget and oncoscience. Dr. Blagosklonny has also served as an associate editor for Cancer Biology and Therapy, Autophagy, Cancer Research, Cell Death and Differentiation, International Journal of Cancer, PLOS ONE, and The American Journal of Pathology.
Mikhail Blagosklonny currently works at the Roswell Park Cancer Institute as a Professor of Oncology. He was appointed in 2009. The professor’s role is to facilitate the development of new anticancer strategies methods of cancer therapy and prevention.
He has worked with the institute to implement their new ideas which include tissue-specific therapy of cancer, protection of healthy cells from radio and chemotherapy, selective combination of cancer drugs, and prevention of cancer by slowing down organismal aging.